Regular Use Of Antithrombotic Drug Increases The Risk Of Nonbiliary Acute Pancreatitis: A Prospective Cohort Study

Chen-yang Wei[1,2†], Ning-ning Mi[1,2,3†], Jin-yu Zhao[1,2], Peng-fei Li[1,2], Zheng-ping An[1,2], Sheng Chen[1,2], Yan-yan Lin[1,2], Ping Yue[1,2], Jin-qiu Yuan[3*] and Wen-bo Meng[1,2*]

Affiliations

[1]*The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.*

[2]*Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.*

[3]*Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.*

* Corresponding Authors:

Professor Wenbo Meng, Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China;

Email: mengwb@lzu.edu.cn.

Professor Jinqiu Yuan, Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China;

Email: yuanjq5@mail.sysu.edu.cn.

†: These authors have contributed equally to this work and share first authorship.

Keywords: Antithrombotic; Acute pancreatitis; Type 2 diabetes mellitus; Hyperlipidemia; Cohort study.

ABSTRACT

Background

Antithrombotic drugs were widely used for cardiovascular disease prevention, but their association with nonbiliary acute pancreatitis remains unclear.

Aim

This study aimed to investigate the association between regular antithrombotic drug use and the risk of nonbiliary pancreatitis in the UK Biobank.

Methods

This prospective cohort study included 431,754 participants from the UK Biobank. Incident nonbiliary acute pancreatitis was identified through links to primary healthcare and hospitalization data. The Cox proportional hazards model estimated the relationship between antithrombotic drug use and nonbiliary acute pancreatitis risk.

Results

During a median follow-up period of 13.73 years, 2,189 nonbiliary acute pancreatitis cases were recorded. Antithrombotic users had a 31% higher risk of nonbiliary acute pancreatitis than non-users (HR = 1.31, 95% CI: 1.08 - 1.61, p = 0.007). Risk varied by specific agent: clopidogrel was associated with a 53% increased risk (HR = 1.53, 95% CI:

1.08 - 2.16, p = 0.016). For warfarin, the overall association was not statistically

significant (HR = 1.32, 95% CI: 0.97 - 1.80, p = 0.076); however, subgroup analysis

indicated that the association was confined to non-diabetic individuals (P-interaction =

0.015; HR = 1.64, 95% CI: 1.15 - 2.35, p = 0.007). No significant associations were

observed for low-dose aspirin and dipyridamole. These results remained robust in

sensitivity analyses, including propensity score matching analysis and lagging the

exposure for one year.

Conclusions:

Regular use of antithrombotic drugs, especially clopidogrel, was associated with an

increased risk of nonbiliary acute pancreatitis. The risk associated with warfarin was

specific to non-diabetic individuals.

Introduction

Acute pancreatitis is an inflammatory disorder of the pancreas associated with substantial morbidity and mortality, imposing a substantial burden on healthcare systems worldwide[1]. In severe cases, it can progress to systemic inflammation and multiple organ failure, with a mortality rate as high as 85%[2]. The etiological spectrum of AP exhibits significant geographical variation: in Western countries, biliary disease is the leading cause, followed by alcoholic and hypertriglyceridemia-induced pancreatitis. However, in Asian countries, including China, hypertriglyceridemia accounts for a substantially higher proportion of cases[3]. The rapidly increasing prevalence of hypertriglyceridemia-related AP has established it as a pressing global health concern[4,5].

Besides the traditional causes, medications are also recognized as potential inducers of AP[6,7]. Antithrombotic agents have drawn particular attention due to their widespread use in patients with cardiovascular diseases[8,9]. However, evidence regarding the association between these drugs and the risk of AP remains notably controversial, with no consensus reached to date. Evidence from animal models suggests a potential protective effect: pretreatment with low-dose warfarin can alleviate ischemia/reperfusion-induced pancreatic injury via this mechanism[10,11]. A recent large-scale clinical study also found that among patients with established AP, the use of low-dose aspirin was associated

with lower mortality and reduced risk of complications[12]. In contrast, other

observational studies have reported an elevated risk[13–16]. This conflicting body of

evidence creates a dilemma for clinicians managing the substantial population of patients

with cardiovascular diseases who require long-term antithrombotic therapy, making it

challenging to assess their potential AP risk.

Given these conflicting findings, a rigorous investigation is warranted to clarify the

relationship between antithrombotic medication use and the risk of acute pancreatitis

(AP). Should these drugs be confirmed as a risk factor, their cardiovascular benefits must

be rigorously weighed against the AP risk in clinical decision-making, necessitating

heightened clinical vigilance among prescribers. Conversely, evidence of a protective

effect would justify further research into mechanisms. To address this knowledge gap, we

conducted a prospective analysis of this association within a large cohort of 431,754

individuals.

Methods

Study Population

The study population was derived from the UK Biobank (UKB), a large prospective

cohort comprising over 500,000 participants aged 37-73 years. The cohort was

established between 2006 and 2010 across 22 assessment centers in England, Wales, and

Scotland. Participants are followed up with regularly for data updates. At recruitment, all individuals completed a baseline questionnaire and underwent assessments that included physical measurements, as well as detailed information on lifestyle and medication use. Further details regarding the UK Biobank cohort have been published elsewhere[17]. Participants with baseline diagnoses of cancer, gallstone disease, or acute pancreatitis were excluded. To prevent gallstone disease from confounding study results, participants who developed acute pancreatitis during follow-up but had previously been diagnosed with gallstone disease were further excluded. Participants lacking follow-up data were also excluded. The final analytical cohort consisted of 431,754 participants (Supplementary Figure 1). All diagnoses were based on International Classification of Diseases-10 (ICD-10) diagnostic criteria.

Exposure assessment

The primary exposure in this study was defined as regular use of antithrombotic drugs at baseline, including anticoagulants and antiplatelet drugs. Specific medications considered were warfarin, low-dose aspirin, clopidogrel, and dipyridamole. At baseline, regular use of antithrombotic drugs was first assessed from participants using a touchscreen questionnaire and then confirmed during verbal interviews with trained staff. In the touchscreen questionnaire, participants were asked, "Do you regularly take any other prescription medications?" "Regular use" of prescription medications was defined as taking them on a long-term and scheduled basis, whether daily, weekly, or monthly

(e.g., depot injections), as reported during the verbal interview. Short-term medications,

such as antibiotic courses, were excluded. If the participant selected "Yes" or "Do not

know," the interviewer would ask: "In the touchscreen, you said you are taking regular

prescription medications. Can you now tell me what these are?" Information on the use of

antithrombotic drugs was recorded using a coded list. The recorded types of

antithrombotic drugs mainly included warfarin, low-molecular-weight heparin, low-dose

aspirin, clopidogrel, and dipyridamole. Information about doses and duration of

antithrombotic agents was not collected. Detailed questions regarding the use of

antithrombotic agents can be found on the UK Biobank website.

Outcome ascertainment

Incident cases of acute pancreatitis (AP) were identified from hospital records linked to

the Health and Social Care Information Centre (England and Wales) and the National

Health Service Central Register (Scotland), using the International Classification of

Diseases (ICD-10) code K85. From these AP cases, nonbiliary acute pancreatitis was

confirmed by excluding those with a concomitant or prior diagnosis of gallstone disease.

Assessment of Covariates

At enrollment, information on covariates was collected through a touchscreen

questionnaire and face-to-face interviews, covering socio-demographic characteristics,

anthropometric measurements, lifestyle factors, medical history, and medication use.

Specifically, the data included: (1) socio-demographic factors: age, sex, ethnicity and socioeconomic status (measured using the Index of Multiple Deprivation, IMD, directly obtained from the UK Biobank); (2) anthropometric data: height and weight, with body mass index (BMI) calculated as kg/m²; (3) lifestyle factors: smoking status, alcohol intake, physical activity (assessed using the short-form International Physical Activity Questionnaire, IPAQ), and healthy diet (defined according to American Heart Association guidelines; Supplementary Table 2); (4) medical history: type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease; (5) medication use: nonsteroidal anti-inflammatory drugs (NSAIDs), hypolipidemic drugs, multivitamin and mineral supplements.

Statistical Analysis

Baseline characteristics are presented as means (standard deviation, SD) for continuous variables and as counts (percentages) for categorical variables. Person-years of follow-up were calculated from the date of assessment for each participant until the first diagnosis of acute pancreatitis, death, or the end of follow-up (May 31, 2022), whichever came first.

Cumulative incidence curves for nonbiliary acute pancreatitis were generated to compare non-users with users of antithrombotic drugs, including anticoagulants, antiplatelet agents, and specific medications. A crude model was first constructed to

examine the association between antithrombotic use and the risk of nonbiliary acute

pancreatitis. Three adjusted models were then established: Model 1 adjusted for age,

gender, ethnicity, and IMD; Model 2 further adjusted for BMI, smoking, alcohol intake,

physical activity, and healthy diet; Model 3 additionally adjusted for type 2 diabetes,

hypertension, hyperlipidemia, NSAID use, hypolipidemic drugs, multivitamin use, and

mineral supplement intake. The proportional hazards assumption was verified using

Schoenfeld residuals for all models, with no violations detected.

Subgroup analyses were conducted according to pharmacological class (anticoagulants

or antiplatelet agents) and by individual drugs (warfarin, aspirin, clopidogrel, and

dipyridamole). Results from the most fully adjusted model (Model 3) are reported as the

primary findings in this study.

We evaluated the potential moderating effects of age, sex, BMI, smoking status,

alcohol intake, physical activity, healthy diet, type 2 diabetes, hypertension,

hyperlipidemia, NSAID intake, hypolipidemic drug intake, multivitamin and mineral

supplement use, using stratified analysis and interaction testing with a likelihood ratio

test in subgroup analyses. Given that type 2 diabetes and hyperlipidemia suggested

potential effect modification in the overall analysis, we also tested their interaction effects

in the aforementioned stratified medication analyses.

To evaluate the robustness of our findings, we performed several sensitivity analyses:

(1) further adjustment for history of cardiovascular diseases in Model 3 (as Model 4); (2)

exclusion of participants who developed the outcome within the first year of follow-up to

minimize reverse causality; and (3) a propensity score matching (PSM) analysis to

evaluate the effect of antithrombotic medication on nonbiliary acute pancreatitis.

All analyses were conducted using R version 4.5.1. A two-tailed P value < 0.05 was

considered statistically significant.

Results

Baseline Characteristics of Participants

Table 1 presents the baseline characteristics of the study participants stratified by

antithrombotic medication use. The study included 431,754 participants, of whom 11,140

were antithrombotic medication users. Among the users, 4,452 used anticoagulants only,

6,610 used antiplatelet agents only, and 78 used both antiplatelet agents and

anticoagulants. In terms of specific medications, 4,397 used warfarin, 2,514 used

low-dose aspirin, 950 used dipyridamole, 2,818 used clopidogrel, and 93 used both

aspirin and clopidogrel. Antithrombotic medication users were more likely to be older,

male, smokers, alcohol consumers, and have a higher prevalence of comorbidities,

including type 2 diabetes, hypertension, and hyperlipidemia.

Antithrombotic Drugs Use and the Risk of Nonbiliary Acute Pancreatitis

During a median follow-up of 13.73 years, 2,189 new cases of nonbiliary acute

pancreatitis were recorded, including 109 cases in the antithrombotic drug user group and

2,080 cases in the non-user group. Compared with non-users, a higher cumulative

incidence of acute pancreatitis was observed in users of antithrombotic drugs, particularly

among users of anticoagulants and clopidogrel (Figure 1a,b and c).

In the crude model, the use of antithrombotic drugs was associated with a 74%

increased risk of nonbiliary acute pancreatitis (HR 1.74, 95% CI 1.44-2.12, $p < 0.001$).

After adjusting for age, sex, ethnicity, and IMD (Model 1), the HR was 1.66 (95% CI,

1.37-2.02; $p < 0.001$). The association attenuated somewhat but remained significant after

further adjustment for lifestyle factors (Model 2) (HR, 1.44; 95% CI, 1.18-1.75; $p <$

0.001). In Model 3, which was further adjusted for comorbidities and medication use, the

result did not change substantially (HR 1.31, 95% CI: 1.08-1.61, $p = 0.007$) (Table 2). In

the analysis by pharmacological class, anticoagulant use demonstrated a significantly

increased risk (HR = 1.37, 95% CI: 1.01-1.86, $p = 0.040$). Specifically, warfarin showed a

trend toward an increased risk, although it did not reach statistical significance (HR =

1.32, 95% CI: 0.97-1.80, $p = 0.076$). Analysis for other anticoagulants could not be

performed or yielded imprecise results due to limitations in sample size. The overall

association for antiplatelet agents was at the margin of statistical significance (HR = 1.27,

95% CI: 0.98-1.64, $p = 0.071$). The use of clopidogrel was associated with a significantly

increased risk (HR = 1.53, 95% CI: 1.08-2.16, $p = 0.016$), whereas neither aspirin (HR =

1.02) nor dipyridamole (HR = 0.95) showed a significant association (Figure 2).

Subgroup Analysis

The analysis revealed significant interactions: the association between overall

antithrombotic drug use and nonbiliary acute pancreatitis risk varied depending on the

presence of diabetes (interaction P-value = 0.001) or hyperlipidemia (interaction P-value

= 0.044). Specifically, among the non-diabetic population, antithrombotic drug use was

significantly associated with an increased risk of nonbiliary acute pancreatitis (HR=1.52,

95% CI: 1.19-1.96, P=0.001). However, this association was not observed in the diabetic

population (HR = 1.08, 95% CI: 0.78-1.50, P = 0.644). The risk increase was more

pronounced in the non-hyperlipidemic population (HR=1.96, 95% CI: 1.22-3.15,

P=0.006), while the association was weaker and did not reach statistical significance in

the hyperlipidemic population (HR=1.23, 95% CI: 0.99-1.53, P=0.063) (Figure 3).

Stratified by drug class, we further evaluated the effect modification by diabetes and

hyperlipidemia. A significant interaction with diabetes was observed among anticoagulant

users (P for interaction = 0.019). Given that warfarin was the predominant anticoagulant

in this study (other anticoagulants were not analyzed due to insufficient sample size), a

subgroup analysis focusing on warfarin confirmed that this interaction remained

statistically significant (P for interaction = 0.015). Specifically, among participants

without diabetes, conventional warfarin use was associated with a 64% increased risk of

244 acute pancreatitis (HR = 1.64, 95% CI: 1.15-2.35), whereas no statistically significant

245 association was observed in participants with diabetes. Furthermore, hyperlipidemia did

246 not show a significant effect-modifying effect on anticoagulants. Among users of

247 antiplatelet agents (including low-dose aspirin, clopidogrel, and dipyridamole), no

248 significant interactions with either diabetes or hyperlipidemia were found

249 (Supplementary Table 3).

250 **Sensitivity Analysis**

251 The association remained stable after further adjustment for history of cardiovascular

252 disease (HR = 1.31, 95% CI: 1.08-1.61). After excluding nonbiliary acute pancreatitis

253 cases that occurred within the first year of follow-up, the association remained

254 statistically significant (HR = 1.25, 95% CI: 1.01-1.54; Supplementary Table 4). In a

255 sensitivity analysis using a propensity score-matched cohort of 55,694 participants

256 (Supplementary Table 5), regular antithrombotic drug use was associated with a 37%

257 increased risk (HR = 1.37, 95% CI: 1.01-1.86).

258 **Discussion**

259 In this prospective cohort study, we found that regular antithrombotic drug use was

260 associated with a 31% increased risk of nonbiliary acute pancreatitis after adjusting for

261 potential confounding factors. In-depth analysis revealed significant heterogeneity in this

262 risk: the increased risk was primarily concentrated in anticoagulants (HR=1.37) and

clopidogrel (HR=1.53), while warfarin showed only a trend toward increased risk, and

aspirin and dipyridamole did not demonstrate significant risk. From a comorbidities

perspective , diabetes and hyperlipidemia significantly modified the overall risk

(interaction P-values: 0.047 and 0.032), with increased risk predominantly observed in

non-diabetic and non-hyperlipidemic individuals. Further pharmacologic stratification

revealed selective modification: Diabetes significantly modified the risk association with

anticoagulants (including warfarin), again predominantly in non-diabetic individuals,

whereas hyperlipidemia showed no significant modification with anticoagulants. No

significant effect modification was observed for either condition with antiplatelet agents.

These findings suggest that patients prescribed anticoagulants or clopidogrel, particularly

those without diabetes, should be monitored for potential symptoms of pancreatitis.

To the best of our knowledge, this is the first prospective cohort study to investigate

the association between the use of antithrombotic drugs and nonbiliary acute pancreatitis.

Although previous research has extensively studied the association between the use of

antithrombotic drugs and cardiovascular diseases[18,19], cerebrovascular disease[20,21],

and risk of liver injury[22,23], their potential pancreatotoxicity has received limited

attention. Notably, some animal studies suggest that pretreatment with agents like low

doses of warfarin may attenuate pancreatic injury in experimental models[10,11].

However, these experimental findings appear to contradict the results of our present study,

which provides the first large-scale epidemiological evidence indicating an increased risk

of nonbiliary acute pancreatitis associated with antithrombotic drug use in humans, with

clopidogrel being a primary contributor. Moreover, we found that diabetes mellitus

significantly modifies the association between warfarin and nonbiliary acute pancreatitis,

and these findings provide important evidence for personalized risk assessment in clinical

practice.

Our study proposes a potential mechanism explaining the increased risk of nonbiliary

acute pancreatitis associated with clopidogrel. Clopidogrel, as a P2Y12 receptor

antagonist, might contribute to pancreatic injury by affecting P2Y12 receptors on

pericytes in the pancreatic microcirculation. Recent studies have shown that P2Y12

receptors are also expressed on vascular smooth muscle cells (VSMCs), where their

activation inhibits the cAMP/protein kinase A pathway[24]. This inhibition effect leads to

dephosphorylation of the cytoskeletal regulator Cofilin, promoting actin

depolymerization and enhanced cell motility[25,26] . Given the high degree of homology

between VSMCs and pericytes, and the established expression of P2RY12 receptors in

pericytes[27], pancreatic pericytes likely also express functional P2Y12 receptors.

Signals transmitted through these receptors regulate cytoskeletal proteins such as

actin-depolymerizing factors, thereby maintaining pericyte adhesion capacity and

cytoskeletal plasticity. Clopidogrel antagonism disrupts this regulation, reducing

cytoskeletal remodeling and increasing pericyte rigidity. This disruption effect

compromises their capillary support function and connections with endothelial cells,

thereby impairing the integrity of the microvascular barrier. The consequent increase in vascular permeability promotes the extravasation of inflammatory mediators and leukocyte infiltration, ultimately triggering or exacerbating local pancreatic inflammation[28,29]. In contrast, aspirin inhibits thromboxane A2 synthesis by acetylating platelet COX-1, an action highly restricted to platelets[30]. Dipyridamole enhances intracellular cAMP levels by inhibiting phosphodiesterase, thereby suppressing platelet activation and promoting vasodilation; it also potentiates these effects by elevating adenosine levels[31]. Since neither drug directly interferes with the P2Y12 receptor signaling pathway, no significant association with acute pancreatitis risk has been observed for either.

Further analysis revealed that anticoagulant use was associated with a significantly increased risk of nonbiliary acute pancreatitis (HR=1.37). Although the risk estimate for warfarin—the most widely used agent in this class—did not reach statistical significance in monotherapy analysis, its risk trend was consistent with the overall class effect, suggesting that a true association might have been obscured by insufficient statistical power in the subgroup analysis. Two possible explanations exist. First, the overall risk signal may be primarily driven by direct oral anticoagulants (DOACs), which could not be analyzed due to sample size limitations. A previous study has reported its association with pancreatitis risk[32]. Second, as a vitamin K antagonist, warfarin inhibits the synthesis of multiple vitamin K-dependent proteins, including matrix Gla protein (MGP).

MGP is a key factor in maintaining vascular homeostasis and suppressing

calcification[33,34]. Warfarin may impair pancreatic microvascular function by inducing

vascular calcification through MGP inhibition, ultimately increasing pancreatic tissue

susceptibility to inflammation. Further analysis revealed that both diabetes and

hyperlipidemia showed significant effect modification at the overall level. However, in

drug-specific analyses, only diabetes confirmed a risk-modifying effect on warfarin

(interaction p=0.015). The signal for hyperlipidemia in the overall analysis may stem

from its interaction with other unanalyzed antithrombotic drugs or remain undetectable

due to insufficient statistical power after sample splitting. Regarding warfarin risk being

primarily concentrated in non-diabetic individuals, we propose the following explanation:

diabetic status often coexists with a hypercoagulable state, which itself constitutes a risk

factor for pancreatic microcirculatory dysfunction and acute pancreatitis[35–37]. In this

context, warfarin's anticoagulant effect may partially improve pancreatic microcirculation,

thereby offsetting its potential risk via the MGP pathway. Conversely, in non-diabetic

individuals with normal coagulation function, warfarin's direct injury mechanism

predominates. Furthermore, the extremely high baseline risk of pancreatitis in diabetic

patients may partially mask the additional relative risk posed by warfarin[38]. In

summary, this study demonstrates that the pancreatitis risk associated with anticoagulants

(particularly warfarin) is not uniformly distributed but is significantly modified by the

patient's diabetic status. This finding underscores the necessity of comprehensively

considering the patient's specific metabolic pathology when assessing the safety of drugs

like warfarin.

Our study has several strengths, including its prospective design, large sample size,

and extended follow-up period. We utilized propensity score matching to enhance

intergroup comparability. Notably, our subgroup analyses systematically identified, for

the first time, that diabetes status is a significant effect modifier of the warfarin-AP

association. The most critical finding—that the risk was elevated primarily in low-risk

individuals (e.g., those without diabetes)—holds profound clinical implications. This

counterintuitive pattern serves as a clear warning, underscoring the imperative of

conducting a thorough benefit-risk assessment before initiating antithrombotic therapy,

even in patients perceived to be at low baseline risk, to avoid underestimating potential

treatment-related hazards.

However, several limitations exist. First, despite rigorous adjustment for known

confounders using propensity score matching, residual confounding may persist due to

the observational design. Second, analyses of specific antithrombotic drug subtypes,

particularly those beyond anticoagulants and clopidogrel, may have been underpowered

due to limited sample sizes. Consequently, while the data suggest potential risk

heterogeneity, definitive conclusions for most subtypes cannot be drawn and require

validation in larger studies. Third, outcome misclassification is possible due to reliance

on medical coding. Finally, as the cohort was predominantly White (94.3%), the

generalizability of our findings to other racial or ethnic groups may be limited,

necessitating future validation in more diverse populations.

Conclusions

This large prospective cohort study establishes that regular antithrombotic medication

use—particularly with clopidogrel—is associated with an increased risk of nonbiliary

acute pancreatitis. Furthermore, it identifies underlying metabolic status as a key modifier

of this risk. Strikingly, diabetes status exerts a negative modifying effect on the

warfarin-associated risk, which was more pronounced in individuals without diabetes.

This counterintuitive finding underscores the necessity of personalized risk assessment in

clinical decision-making for antithrombotic therapy, with particular vigilance warranted

in seemingly "healthy" populations. Future research should prioritize elucidating the

underlying biological mechanisms and validating these findings at the level of specific

drug subtypes in additional high-quality cohorts.

Data availability statement

UK Biobank is an open-access resource, and the study website

https://www.ukbiobank.ac.uk/ provides information on available data and access

procedures. Data sets used for analysis will be made available upon reasonable request.

Ethics statement

Ethics approval for the UK Biobank was granted by the North West Multi-Centre

Research Ethics Committee in 2006 and was updated regularly after that

(https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). All

participants provided informed written consent to take part in the study and be

followed-up through linkage to health-related records. Concerning the sensitivity of

genetic data, the UK Biobank strictly prohibits researchers from using any genetic or

other data to identify participants. This would violate the legal agreement researchers

signed when they were granted access to the UK Biobank data.

Author Contributions

CW: Writing - original draft, Visualization, Investigation, Data curation, Formal analysis,

Conceptualization. NM: Writing - original draft, Methodology, Formal analysis. JZ:

Investigation, Methodology, Formal analysis. PL: Validation, Methodology. ZA:

Methodology. SC: Visualization, Investigation. YL: Writing - review & editing. PY:

Writing - review & editing. JY: Writing - review & editing, Supervision, Formal analysis.

WM: Writing - review & editing, Supervision, Funding acquisition.

Funding

This work was supported by the Major Program of the Gansu Province Joint Scientific Research Fund (23JRRA1488); Major Scientific and Technological Innovation Project of Gansu Provincial Health Industry (GSWSQNPY2024-10); and the Lanzhou Talent Innovation and Entrepreneurship Project (2022-3-42).

Acknowledgements

We thank all participants and researchers from the UK Biobank who make the study possible.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

During the writing process of this work, the authors used DeepSeek-R1 in order to improve language only. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Reference

[1] Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol 2019;16:479–96. https://doi.org/10.1038/s41575-019-0158-2.

[2] Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol 2014;20:13879–92. https://doi.org/10.3748/wjg.v20.i38.13879.

[3] Han K, Chen S, Song Y, Du C, Gao F, Liu S, He Y, Chai N, Linghu E, Liu M. Burden of pancreatitis and associated risk factors in China, 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Chin Med J (Engl) 2022;135:1340–7. https://doi.org/10.1097/CM9.0000000000002164.

[4] van Geenen EJM, van der Peet DL, Bhagirath P, Mulder CJJ, Bruno MJ. Etiology and diagnosis of acute biliary pancreatitis. Nat Rev Gastroenterol Hepatol 2010;7:495–502. https://doi.org/10.1038/nrgastro.2010.114.

[5] Scherer J, Singh V, Pitchumoni CS, Yadav D. Issues in Hypertriglyceridemic Pancreatitis - An Update. J Clin Gastroenterol 2014;48:195–203. https://doi.org/10.1097/01.mcg.0000436438.60145.5a.

[6] Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, Beyer G, Sutton R. Acute Pancreatitis: Diagnosis and Treatment. Drugs 2022;82:1251–76. https://doi.org/10.1007/s40265-022-01766-4.

[7] **Xie H**, **Jiang L**, Peng J, Hu H, Han M, Zhao B. Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology. Front Pharmacol 2025;16:1564127.

https://doi.org/10.3389/fphar.2025.1564127.

[8] World Health Organization. The selection and use of essential medicines, 2025:

WHO Model List of Essential Medicines, 24th list. World Health Organization;

2025. https://doi.org/10.2471/B09474.

[9] Zhang W, Yu E, Zhao W, Wu C, Ji X. Secondary prevention for intracranial

atherosclerotic stenosis: Where we stand and challenges ahead. J Transl Intern Med

2024;12:537–9. https://doi.org/10.1515/jtim-2024-0037.

[10] Maduzia D, Ceranowicz P, Cieszkowski J, Gałązka K, Kuśnierz-Cabala B,

Warzecha Z. Pretreatment with Warfarin Attenuates the Development of

Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats. Mol Basel Switz

2020;25:2493. https://doi.org/10.3390/molecules25112493.

[11] Konarska-Bajda K, Ceranowicz P, Cieszkowski J, Ginter G, Stempniewicz A,

Gałązka K, Kuśnierz-Cabala B, Dumnicka P, Bonior J, Warzecha Z. Administration

of Warfarin Inhibits the Development of Cerulein-Induced Edematous Acute

Pancreatitis in Rats. Biomolecules 2023;13:948.

https://doi.org/10.3390/biom13060948.

[12] **Kim DH**, **Ko D**, Elizondo Alatorre C, Lukens FJ, Porres JA, Palacios Argueta P,

Raimondo M, Ji B, Bi Y, Kröner PT. Low-dose aspirin use is associated with

reduced 30- and 90-day mortality and overall improved outcomes in patients with

acute pancreatitis: A multinational multicenter analysis. Pancreatology

2025;25:1080–5. https://doi.org/10.1016/j.pan.2025.09.022.

[13] Wilks AB, Douce D, Ades S, Cushman M, Zakai NA, Holmes CE. Bleeding Risk in

a Cohort of Ambulatory Cancer Patients Receiving Outpatient Prophylactic

Anticoagulation for Venous Thrombosis Prevention. Blood 2019;134:709.

https://doi.org/10.1182/blood-2019-128831.

[14] Chilbert MR, Gressel L, Lee L, Kersten B, Zammit K, Woodruff AE. Use of

Prophylactic or Therapeutic Anticoagulation in Critically Ill Patients With

Pre-existing Atrial Fibrillation. Hosp Pharm 2025;60:232–8.

https://doi.org/10.1177/00185787241295997.

[15] **Yin Y**, **Wang L**, Gao F, Liu L, Qi X. Anticoagulation Therapy for Splanchnic Vein

Thrombosis Associated With Acute Pancreatitis: A Systematic Review and

Meta-Analysis. Clin Appl Thromb Off J Int Acad Clin Appl Thromb

2023;29:10760296231188718. https://doi.org/10.1177/10760296231188718.

[16] Norton W, Lazaraviciute G, Ramsay G, Kreis I, Ahmed I, Bekheit M. Current

practice of anticoagulant in the treatment of splanchnic vein thrombosis secondary

to acute pancreatitis. Hepatobiliary Pancreat Dis Int HBPD INT 2020;19:116–21.

https://doi.org/10.1016/j.hbpd.2019.12.007.

[17] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P,

Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen

T, Peakman T, Collins R. UK biobank: an open access resource for identifying the

causes of a wide range of complex diseases of middle and old age. PLoS Med

2015;12:e1001779. https://doi.org/10.1371/journal.pmed.1001779.

[18] Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K,

Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators.

Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N

Engl J Med 2019;381:1103–13. https://doi.org/10.1056/NEJMoa1904143.

[19] Song PS, Park YH, Oh J-H, Song YB, Choi S-H, Gwon H-C, Cho D-K, Rha S-W,

Bae J-W, Jeong J-O, Hahn J-Y, SMART-DATE and the SMART-CHOICE

investigators. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet

Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis

of the SMART-DATE and SMART-CHOICE Trials. Am J Cardiol 2021;150:47–54.

https://doi.org/10.1016/j.amjcard.2021.03.053.

[20] Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L,

Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC, CHANCE

Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic

attack. N Engl J Med 2013;369:11–9. https://doi.org/10.1056/NEJMoa1215340.

[21] Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS,

Lindblad AS, Palesch YY, Clinical Research Collaboration, Neurological

Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel

and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med

2018;379:215–25. https://doi.org/10.1056/NEJMoa1800410.

[22] Alonso A, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL,

Lutsey PL. Prospective study of oral anticoagulants and risk of liver injury in

patients with atrial fibrillation. Heart 2017;103:834–9.

https://doi.org/10.1136/heartjnl-2016-310586.

[23] Björnsson HK, Gudmundsson DO, Björnsson ES. Liver injury caused by oral

anticoagulants: A population-based retrospective cohort study. Liver Int Off J Int

Assoc Study Liver 2020;40:1895–900. https://doi.org/10.1111/liv.14559.

[24] Wihlborg A-K, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T,

Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and

stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol

2004;24:1810–5. https://doi.org/10.1161/01.ATV.0000142376.30582.ed.

[25] Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system.

Biochem J 1998;336 (Pt 3):513–23. https://doi.org/10.1042/bj3360513.

[26] Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C, Gadeau A-P. Nucleotide

receptors involved in UTP-induced rat arterial smooth muscle cell migration. Circ

Res 2002;90:678–81. https://doi.org/10.1161/01.res.0000013700.98464.8e.

[27] **Barnett SN**, **Cujba A-M**, **Yang L**, Maceiras AR, Li S, Kedlian VR, Pett JP,

Polanski K, Miranda AMA, Xu C, Cranley J, Kanemaru K, Lee M, Mach L, Perera

S, Tudor C, Joseph PD, Pritchard S, Toscano-Rivalta R, Tuong ZK, Bolt L,

Petryszak R, Prete M, Cakir B, Huseynov A, Sarropoulos I, Chowdhury RA,

Elmentaite R, Madissoon E, Oliver AJ, Campos L, Brazovskaja A, Gomes T,

Treutlein B, Kim CN, Nowakowski TJ, Meyer KB, Randi AM, Noseda M,

Teichmann SA. An organotypic atlas of human vascular cells. Nat Med

2024;30:3468–81. https://doi.org/10.1038/s41591-024-03376-x.

[28] Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. Br J Surg 2006;93:518–30. https://doi.org/10.1002/bjs.5316.

[29] Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute pancreatitis. J Hepatobiliary Pancreat Surg 2001;8:187–94. https://doi.org/10.1007/s005340170015.

[30] Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J 2024;45:2362–76. https://doi.org/10.1093/eurheartj/ehae324.

[31] Ali Hassan R, Patel P. Dipyridamole. StatPearls, Treasure Island (FL): StatPearls Publishing; 2025.

[32] Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol 2007;5:648-661.e3. https://doi.org/10.1016/j.cgh.2006.11.023.

[33] Danziger J. Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification. Clin J Am Soc Nephrol CJASN 2008;3:1504–10. https://doi.org/10.2215/CJN.00770208.

[34] Willems BAG, Vermeer C, Reutelingsperger CPM, Schurgers LJ. The realm of vitamin K dependent proteins: Shifting from coagulation toward calcification. Mol Nutr Food Res 2014;58:1620–35. https://doi.org/10.1002/mnfr.201300743.

[35] Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44–54. https://doi.org/10.1016/s1056-8727(00)00132-x.

[36] Chung KH, Cho IR, Choi YH, Cho YD, Ryu JK, Lee SH, Han K. Association between diabetic status and risk of acute pancreatitis: A nationwide population-based study. J Evid-Based Med 2024;17:588–96. https://doi.org/10.1111/jebm.12637.

[37] Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:225–31. https://doi.org/10.1097/MEG.0b013e32835af154.

[38] Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, Maeda R. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PloS One 2012;7:e53224. https://doi.org/10.1371/journal.pone.0053224.

Author names in bold designate shared co-first authorship

Figure legends

Figure 1. Cumulative Incidence of Nonbiliary Acute Pancreatitis Among Users of Antithrombotic Drugs, Antiplatelet or Anticoagulant Drugs, and Specific Agents Compared with Non-Users.

Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. **Figure 1a** shows the cumulative incidence of nonbiliary acute pancreatitis in overall antithrombotic drug users and non-users. **Figure 1b** shows the cumulative incidence of nonbiliary acute pancreatitis in antiplatelet drug users, anticoagulant drug users, and non-users. **Figure 1c** shows the cumulative incidence of nonbiliary acute pancreatitis in clopidogrel, warfarin, aspirin, dipyridamole users, and non-users. IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug; nonbiliary acute pancreatitis, non-gallstone acute pancreatitis**.**

Figure 2. Association of Antithrombotic Drug Use with Nonbiliary Acute Pancreatitis: An Analysis of Overall, Stratified, and Individual Medication Effects.

Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary

characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake,

Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. IMD,

index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal

anti-inflammatory drug**.**

Figure 3. Subgroup analyses of Antithrombotic use and the risk of Nonbiliary

Acute Pancreatitis.

Estimated effects were calculated using the Cox model adjusted by age, gender,

ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary

characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake,

Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. IMD,

index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal

anti-inflammatory drug**.**

Table 1. Baseline characteristics of participants by antithrombotic use in the UK Biobank

| Characteristics | Antithrombotic use | | Overall |
	No（N=420,614）	Yes　(N=11,140)	
Number of participants	(N=420614)	(N=11140)	(N=431754)
Anticoagulant only	/	4,452	/
Warfarin	/	4,397	/
Antiplatelet only	/	6,610	/
Low-dose Aspirin	/	2,514	/
Dipyridamole	/	950	/
Clopidogrel	/	2,818	/
Aspirin and Clopidogrel	/	93	/
Anticoagulant and Antiplatelet	/	78	/
Mean (SD)age	56.2 (8.10)	61.7 (6.26)	56.3 (8.11)
Male	195105 (46.4%)	7799 (70.0%)	202904 (47.0%)
White	396396 (94.2%)	10502 (94.3%)	406898 (94.2%)
Mean (SD) Index of Multiple Deprivation	17.2 (13.8)	19.4 (15.3)	17.2 (13.8)
Mean (SD)BMI	27.3 (4.71)	29.2 (5.18)	27.4 (4.73)
Smoking	187613 (44.6%)	6454 (57.9%)	194067 (44.9%)
Drinking	/	/	/
Never	79126 (18.8%)	2810 (25.2%)	81936 (19.0%)
Low	46553 (11.1%)	1104 (9.9%)	47657 (11.0%)
Moderate	207958 (49.4%)	4751 (42.6%)	212709 (49.3%)
High	86632 (20.6%)	2461 (22.1%)	89093 (20.6%)
Physical activity	/	/	/
High	135361 (32.2%)	3047 (27.4%)	138408 (32.1%)

Low	59600 (14.2%)	1929 (17.3%)	61529 (14.3%)
Moderate	132826 (31.6%)	3379 (30.3%)	136205 (31.5%)
HealthyDiet	212118 (50.4%)	5768 (51.8%)	217886 (50.5%)
NASIDS	69906 (16.6%)	699 (6.3%)	70605 (16.4%)
Hypolipidemic drug	71717 (17.1%)	8142 (73.1%)	79859 (18.5%)
Vitamin	63113 (15.0%)	1636 (14.7%)	64749 (15.0%)
Mineral	91240 (21.7%)	1596 (14.3%)	92836 (21.5%)
Diabetes	34044 (8.1%)	3028 (27.2%)	37072 (8.6%)
Hypertension	305680 (72.7%)	9819 (88.1%)	315499 (73.1%)
Hyperlipidemia	201352 (47.9%)	9363 (84.0%)	210715 (48.8%)
Myocardial Infarction	16671 (4.0%)	439 (3.9%)	17110 (4.0%)
Coronary Heart Disease	22737 (5.4%)	599 (5.4%)	23336 (5.4%)
Myocardial Infarction	4624 (1.1%)	136 (1.2%)	4760 (1.1%)
Peripheral Vascular Disease	6987 (1.7%)	188 (1.7%)	7175 (1.7%)
Stroke	6638 (1.6%)	187 (1.7%)	6825 (1.6%)

613   Abbreviations: SD, standard deviation; BMI, body mass index; NSAIDs, non-steroidal

614   anti-inflammatory drugs;

615   Values are numbers (percentages) unless stated otherwise.

617   **Table 2. Associations between Antithrombotic use and risk of Nonbiliary Acute**

618   **Pancreatitis(n=431,754).**

Variables	Antithrombotic use		p-value
	No （N=420,614）	Yes （N=11,140)	
Case/person-years	2,080 / 5,652,141	109 / 139,161	
IR (per 10,000 person-years)	3.68	7.83	
Multivariate-adjusted HR (95% CI)			
Crude model	1.00 (Reference)	1.74 （1.44-2.12）	<0.001

model 1	1.00 (Reference)	1.66 (1.37-2.02)	<0.001
model 2	1.00 (Reference)	1.44 (1.18-1.75)	<0.001
model 3	1.00 (Reference)	1.31 (1.08-1.61)	0.007

Crude model: Unadjusted for covariates in the crude model;Model 1 adjusted for age,

gender, ethnicity, and Index of Multiple Deprivation (IMD);Model 2 additionally adjusted

for BMI, smoking status, alcohol intake, physical activity, and dietary characteristics;

Model 3 further adjusted for comorbidities and medication use on the basis of Model 2,

including type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic

drugs, multivitamins, and mineral supplements.

Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; BMI, body

mass index; NSAID, nonsteroidal anti-inflammatory drug.

Figure 1. All adjusted HRs were adjusted for the following covariates: age, gender,

ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary

characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake,

Hypolipidemic drug intake, multivitamin use and intake of mineral supplements.

Abbreviations: HR, hazard ratio; CI, confidence interval; IMD, index of multiple

deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Figure 2. The model was adjusted for age, gender, ethnicity, the Index of Multiple

Deprivation (IMD), BMI, smoking status, alcohol intake, physical activity, dietary

characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake,

hypolipidemic drug intake, multivitamin use, and mineral supplement intake;

Abbreviations: BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Drugs	Case/Person-years	HR（95%CI）	P
Antithrombotic	109/139161	1.31（1.08-1.61）	0.007
Anticoagulant_only	44/54597	1.37（1.01-1.86）	0.040
Warfarin	42/53935	1.32（0.97-1.80）	0.076
Antiplatelet_only	64/83690	1.27（0.98-1.64）	0.071
Clopidogrel	34/35488	1.53（1.08-2.16）	0.016
Aspirin	19/32473	1.02（0.65-1.61）	0.934
Dipyridamole	7/11735	0.95（0.45-2）	0.890

656
657
658
659

Figure 3. Estimated effects were calculated using the Cox model adjusted by age, gender,

ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary

characteristics, type 2 diabetes, hypertension, Hyperlipidemia, NSAID intake,

multivitamin use, Hypolipidemic drug intake and intake of mineral supplements;

Abbreviations: HR, hazard ratio; CI, confidence interval; IMD, index of multiple

deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Subgroup	non-antithrombotic use case	non-antithrombotic use person-years	antithrombotic use case	antithrombotic use person-years	Multivariate-adjusted HR(95% CI)	P Value	P for Interaction
Age							0.910
(35,55]	709	2525127	13	22793	1.19 (0.68-2.09)	0.546	
(55,65]	947	2390321	54	73533	1.28 (0.96-1.70)	0.088	
(65,75]	424	736694	42	42836	1.40 (1.00-1.94)	0.047	
Gender							0.889
Female	1020	3054433	32	42929	1.33 (0.93-1.92)	0.118	
Male	1060	2597708	77	96233	1.30 (1.02-1.66)	0.031	
BMI							
less than 25kg/m2	426	1880600	19	26497	1.71 (1.05-2.77)	0.03	
25-30 kg/m2	870	2428087	34	61463	1.14 (0.80-1.62)	0.479	
at least 30 kg/m2	777	1315281	56	50872	1.36 (1.03-1.80)	0.033	
Smoking							0.741
Yes	1101	2494024	69	78884	1.28 (0.99-1.65)	0.055	
No	968	3138831	40	59393	1.41 (1.02-1.96)	0.038	
Drinking							0.544
Never	526	1051145	33	34437	1.32 (0.91-1.90)	0.138	
Low	233	627878	8	13875	1.03 (0.50-2.12)	0.946	
Moderate	907	2809485	48	59700	1.47 (1.09-1.99)	0.012	
High	409	1159129	20	30975	1.19 (0.75-1.89)	0.464	
Physical Activity							0.650
Low	935	2856079	51	72992	1.55 (1.02-2.33)	0.038	
Moderate	1145	2796062	58	66169	1.52 (1.05-2.20)	0.027	
High	562	1823065	21	39167	1.00 (0.64-1.57)	0.99	
Diet							0.968
Healthy	341	798247	27	23389	1.27 (0.95-1.70)	0.112	
Unhealthy	611	1789408	32	42241	1.36 (1.03-1.79)	0.028	
Hyperlipidemia							0.044
Yes	1301	2684075	91	116556	1.23 (0.99-1.53)	0.644	
No	779	2968066	18	22605	1.96 (1.22-3.15)	0.001	
Diabetes							0.010
Yes	461	440728	40	36479	1.08 (0.78-1.50)	0.015	
No	1619	5211413	69	102682	1.52 (1.19-1.96)	0.179	
Hypertension							0.614
Yes	1670	4087924	98	122365	1.30 (1.05-1.61)	0.063	
No	407	1559938	11	16782	1.54 (0.82-2.87)	0.006	
NSAIDs							0.676
Yes	360	942313	7	8732	1.19 (0.55-2.56)	0.659	
No	1720	4709828	102	130429	1.32 (1.07-1.62)	0.009	
Hypolipidemic drug							0.361
yes	539	934428	81	100727	1.40 (0.87-2.25)	0.162	
no	1541	4717713	28	38434	1.23 (0.99-1.53)	0.057	
Vitamin							0.583
Yes	328	844741	19	20443	1.43 (0.88-2.32)	0.144	
No	1752	4807400	90	118718	1.28 (1.03-1.60)	0.027	
Mineral							0.867
Yes	415	1229229	14	20387	1.20 (0.69-2.08)	0.514	
No	1665	4422912	95	118774	1.33 (1.07-1.65)	0.009	

0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50